This section is intended for UK healthcare professionals. If you are a member of the public click here. If you have been prescribed Ninlaro click here.

REAL WORLD EVIDENCE

NRd European real world data

Retrospective analysis of RRMM patients who received NRd in three European countries1

Patient Demographic n=138
Median age, years (range) 68 (40-92)

ECOG status

  • 0-1
  • 2-3
  • 78.1%
  • 27.2%
Median prior lines (range) 1.5 (1-7)
Prior bortezomib 89.1%
Prior lenalidomide 26.1%
Median follow-up, months 9.1 months
Median treatment duration 7.2 months (1.0-27.5)

NRd has demonstrated real world efficacy similar to clinical trial1

Efficacy data for RRMM patients who received NRd in three European countries.
Median responses (n=138)1

Results Median 95% CI
ORR 68.5% 48.8-72.4
PFS 27.6 months 11.3-27.6
TTP 27.6 months 15.2-27.6
Time to first response 1.3 months -

Type and duration of responses (n=138)1

Patients treated with NRd for ≥6 months were 9.5 times more likely to achieve a best response of PR or better, compared with those treated for <6 months (n=138; adjusted OR 9.50; 95% CI 2.51, 36.02; p=0.001) 1

Adapted from Terpos E et al. 2017.

NRd has demonstrated real world tolerability similar to clinical trial1

Adverse event Patients, %
Peripheral neuropathy
  • Resolved
  • Unresolved Grade 1 or 2
28.3
  • 38.5
  • 61.5
Pneumonia 8.0
Hypertension 5.9
Deep vein thrombosis 3.6
Herpes zoster infection 2.9
  • No cardiac events or bone fractures were recorded in this study
  • 11 deaths were observed on the study, 4 of which were due to PD